Genetic Technologies Limited logo
Genetic Technologies Limited GENE

Annual report 2022
added 08-30-2022

report update icon

Genetic Technologies Limited Financial Ratios 2011-2026 | GENE

Annual Financial Ratios Genetic Technologies Limited

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-1293.0 -2414.4 -2640.3 -2.4 -4.8 -2.0 -4.1 -3.7 -2.3 -5.7 -14.4 118.2

P/S

1357.0 141748.2 1684921.9 605.5 138.3 32.8 41.6 16.0 5.0 15.7 20.6 5.9

EPS

-0.1 -0.1 -0.1 - - - - - - - - -

EV (Enterprise Value)

9.21 B 17.1 B 16.6 B 11 M 15.8 M 3.42 M 27.4 M 7.86 M 22.3 M 42.7 M 59.6 M 83.6 M

EBITDA per Share

- - - -1.27 -1.3 -1.99 -2.67 -4.97 -9.27 -10.4 -12.7 2.3

EV/EBITDA

- -2.7 -1.6 -2.5 -0.3 -1.8 -0.6 -1.8 -4.4 -4.7 45.9

PEG

62.59 0.2 -0.26 0.11 0.11 0.1 0.07 0.21 -0.08 0.02 -1.09

P/B

561.2 793.6 1187.8 8.7 5.6 1.6 2.9 1.7 12.6 9.2 5.3 15.8

P/CF

-1629.2 -2714.2 -2909.6 -1.9 -3.5 -1.8 -3.2 -2.5 -1.6 -5.3 -7.4 38.9

ROE %

-43.40 -32.87 -44.99 -362.78 -115.96 -79.44 -71.18 -46.47 -554.04 -161.48 -36.71 13.35

ROA %

-34.28 -30.81 -40.27 -196.80 -88.61 -69.41 -63.65 -42.52 -150.47 -111.77 -32.16 10.20

ROCE %

- - - -347.69 -126.76 -74.40 -71.61 -51.39 -223.37 -156.21 -75.94 15.19

Current Ratio

4.8 16.0 9.5 2.1 4.1 7.9 9.1 11.3 1.9 1.1 5.2 3.1

DSO

- - - 11745.4 581.3 300.1 279.2 129.7 88.9 35.5 49.0 13.5

DIO

- - - 42.1 71.8 56.9 82.0 130.0 42.3 40.1 59.3 -

DPO

- - - 779.8 651.8 295.2 192.7 211.8 178.8 116.7 62.3 200.0

Operating Cycle

- - - 11787.5 653.0 357.0 361.2 259.7 131.2 75.6 108.4 13.5

Cash Conversion Cycle

- - - 11007.7 1.2 61.8 168.5 48.0 -47.6 -41.1 46.1 -186.5

All numbers in AUD currency

Quarterly Financial Ratios Genetic Technologies Limited

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Current Ratio

- - 4.8 - - - 16.0 - - - 9.5 - 2.9 - 2.2 - - - 4.2 - - - 7.9 - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in AUD currency

Multiples are an important financial analysis tool for the company Genetic Technologies Limited, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Biodesix Biodesix
BDSX
$ 15.24 -1.96 % $ 1.98 B usaUSA
Biomerica Biomerica
BMRA
$ 2.08 -3.85 % $ 4.78 M usaUSA
Bioventus Bioventus
BVS
$ 9.24 0.98 % $ 616 M usaUSA
DexCom DexCom
DXCM
$ 66.58 -0.03 % $ 26 B usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
$ 104.91 - $ 19.8 B usaUSA
Fulgent Genetics Fulgent Genetics
FLGT
$ 16.7 2.23 % $ 505 M usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Guardant Health Guardant Health
GH
$ 85.85 2.7 % $ 10.8 B usaUSA
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
IDEXX Laboratories IDEXX Laboratories
IDXX
$ 570.7 0.09 % $ 45.9 B usaUSA
Illumina Illumina
ILMN
$ 125.83 -0.12 % $ 20 B usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Co-Diagnostics Co-Diagnostics
CODX
$ 4.4 101.83 % $ 129 M usaUSA
Lantheus Holdings Lantheus Holdings
LNTH
$ 75.01 1.04 % $ 5.06 B usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Medpace Holdings Medpace Holdings
MEDP
$ 461.77 0.22 % $ 13.3 B usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
$ 163.35 2.61 % $ 8.1 B usaUSA
IQVIA Holdings IQVIA Holdings
IQV
$ 166.57 0.29 % $ 28.6 B usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 270.03 0.44 % $ 26.2 B schweizSchweiz
Myriad Genetics Myriad Genetics
MYGN
$ 4.72 2.39 % $ 437 M usaUSA
Neogen Corporation Neogen Corporation
NEOG
$ 9.31 2.2 % $ 2.02 B usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
National Research Corporation National Research Corporation
NRC
$ 17.49 0.29 % $ 391 M usaUSA
Natera Natera
NTRA
$ 198.72 2.16 % $ 19.6 B usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
Interpace Biosciences Interpace Biosciences
IDXG
$ 1.71 - $ 7.5 M usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
$ 1.42 2.0 % $ 426 M usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Personalis Personalis
PSNL
$ 8.19 5.27 % $ 485 M usaUSA
Precipio Precipio
PRPO
$ 28.0 5.26 % $ 36.3 M usaUSA
RadNet RadNet
RDNT
$ 61.19 2.2 % $ 4.6 B usaUSA
Celcuity Celcuity
CELC
$ 109.08 6.93 % $ 4.3 B usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 266.06 -0.02 % $ 22.1 B usaUSA
Senseonics Holdings Senseonics Holdings
SENS
$ 6.85 2.85 % $ 286 M usaUSA
Sotera Health Company Sotera Health Company
SHC
$ 13.9 0.47 % $ 3.95 B usaUSA